TY - JOUR
T1 - Rosuvastatin treatment is associated with a decrease of serum oxidised low-density lipoprotein/beta2-glycoprotein i complex concentration in type 2 diabetes
AU - Ames, Paul Rj
AU - Ortiz-Cadenas, Alfredo
AU - Garcia-De La Torre, Ignacio
AU - Nava, Arnulfo
AU - Oregon-Miranda, Aldo
AU - Batuca, Joana R.
AU - Kojima, Kazuo
AU - Lopez, Luis R.
AU - Matsuura, Eiji
PY - 2010/11
Y1 - 2010/11
N2 - Aims To evaluate the effect of rosuvastatin on oxidised low-density lipoprotein/beta2-glycoprotein I (oxLDL/ β2GPI) complex concentration in type 2 diabetes mellitus. Methods: open label 2:1 assignment of consecutive diabetic patients into oral rosuvastatin (10 mg daily for six weeks) arm or observational arm with measurements of serum oxLDL/ β2GPI complexes, nitric oxide metabolites, asymmetric dimethyl arginine, nitrotyrosine alongside routine biochemistry at baseline and end of study in all patients. Results After rosuvastatin treatment the mean serum concentration of oxLDL/β2GPI decreased from 0.79±0.49 units/mL to 0.53±0.36 units/mL (p<0.001). The decrease was statistically independent from the decrements of mean cholesterol, LDL and triglyceride concentrations (p<0.001) but probably dependent on the decrement of nitrate (p<0.001). Conclusion In type 2 diabetes, treatment with rosuvastatin was associated with a significant reduction of serum concentrations of oxLDL/β2GPI complexes, which is in further support of the already proposed effects of the drug on the oxidative metabolism of lipids and/or LDL. The oxLDL/β2GPI complex may represent a surrogate marker of oxidative stress in type 2 diabetes.
AB - Aims To evaluate the effect of rosuvastatin on oxidised low-density lipoprotein/beta2-glycoprotein I (oxLDL/ β2GPI) complex concentration in type 2 diabetes mellitus. Methods: open label 2:1 assignment of consecutive diabetic patients into oral rosuvastatin (10 mg daily for six weeks) arm or observational arm with measurements of serum oxLDL/ β2GPI complexes, nitric oxide metabolites, asymmetric dimethyl arginine, nitrotyrosine alongside routine biochemistry at baseline and end of study in all patients. Results After rosuvastatin treatment the mean serum concentration of oxLDL/β2GPI decreased from 0.79±0.49 units/mL to 0.53±0.36 units/mL (p<0.001). The decrease was statistically independent from the decrements of mean cholesterol, LDL and triglyceride concentrations (p<0.001) but probably dependent on the decrement of nitrate (p<0.001). Conclusion In type 2 diabetes, treatment with rosuvastatin was associated with a significant reduction of serum concentrations of oxLDL/β2GPI complexes, which is in further support of the already proposed effects of the drug on the oxidative metabolism of lipids and/or LDL. The oxLDL/β2GPI complex may represent a surrogate marker of oxidative stress in type 2 diabetes.
KW - diabetes
KW - oxidative stress
KW - oxidised low-density lipoprotein/beta2- glycoprotein I
UR - http://www.scopus.com/inward/record.url?scp=79751475968&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79751475968&partnerID=8YFLogxK
U2 - 10.1177/1474651410388057
DO - 10.1177/1474651410388057
M3 - Article
AN - SCOPUS:79751475968
SN - 1474-6514
VL - 10
SP - 292
EP - 299
JO - British Journal of Diabetes and Vascular Disease
JF - British Journal of Diabetes and Vascular Disease
IS - 6
ER -
